Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 15/20 | 0.38 |
| ▸ | JAK1 | P23458 | 10/20 | 0.38 |
| ▸ | JAK3 | P52333 | 14/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.38 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.38 |
| ▸ | LCK | P06239 | 2/20 | 0.38 |
| ▸ | RET | P07949 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | CAMK1D | Q8IU85 | 2/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | LTK | P29376 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | PRKX | P51817 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 5/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16478691 | 0.83 | JAK3 (0.43) | JAK2JAK1JAK3ROCK1PKN2 | |
| SCHEMBL15014550 | 0.83 | JAK3 (0.43) | JAK2JAK1JAK3ROCK1PKN2 | |
| SCHEMBL12683327 | 0.83 | JAK3 (0.43) | JAK2JAK1JAK3ROCK1PKN2 | |
| SCHEMBL16478644 | 0.80 | IRAK4 (0.41) | JAK2JAK1JAK3TYK2MEN1 | |
| SCHEMBL24456492 | 0.80 | JAK2 (0.40) | JAK2JAK1JAK3ROCK1PKN2 | |
| SCHEMBL12424401 | 0.80 | JAK2 (0.40) | JAK2JAK1JAK3ROCK1PKN2 | |
| SCHEMBL30497410 | 0.80 | JAK2 (0.40) | JAK2JAK1JAK3ROCK1PKN2 | |
| SCHEMBL12384653 | 0.79 | JAK2 (0.39) | JAK2JAK1JAK3ROCK1PKN2 | |
| SCHEMBL12424943 | 0.79 | ALDH1A1 (0.43) | JAK2JAK1JAK3ROCK1PKN2 | |
| SCHEMBL19012676 | 0.78 | JAK2 (0.36) | JAK2JAK1JAK3ROCK1PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | JAK2 122/4885JAK1 434/4885JAK3 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.